AI Article Synopsis
- The study investigates the role of amyloid precursor protein (APP) and amyloid-beta (Abeta) in the death of retinal ganglion cells in glaucoma, focusing on their distribution in C57BL/6 mice.
- After inducing chronic ocular hypertension in the mice, immunohistochemistry was used to analyze the levels of APP and Abeta in the retinas, revealing significant differences between hypertensive and control eyes.
- The findings indicate that elevated intraocular pressure likely causes abnormal processing of APP, leading to increased levels of both APP and Abeta in the retinas affected by glaucoma.
Article Abstract
Purpose: Amyloid precursor protein (APP) and amyloid-beta (Abeta) appear to participate in the pathophysiology of retinal ganglion cell (RGC) death in glaucoma. We, therefore, determined the distribution of APP and Abeta in the retinas of C57BL/6 mice after induction of chronic ocular hypertension.
Methods: Ocular hypertension was induced in one eye of three-month-old C57BL/6 mice by injection of hypertonic saline into episcleral veins. After 6 weeks of documented elevated intraocular pressure (IOP), retinas were fixed with 4% paraformaldehyde and processed for immunohistochemistry with antibodies including a polyclonal antibody to the C-terminus of Abeta 40 (Novartis 17-40/23) and a polyclonal antibody to the APP ectodomain (Novartis 474). Distribution and semiquantitative expression of APP and Abeta immunolabeling in ocular hypertensive and control retinas were graded in a masked fashion and compared.
Results: APP and Abeta immunoreactivity was found in the pia/dura, optic nerve (ON), and RGC layer of ocular hypertensive retinas, whereas APP and Abeta immunoreactivity in the contralateral control eyes was detected only in the pia/dura. Comparison of ocular hypertensive and control eyes for Abeta immunolabeling was significant in the ON and RGC layer (p < 0.05) whereas no significant difference was found when compared for APP staining.
Conclusions: High Abeta and APP levels were seen in ocular hypertensive retinas, probably due to abnormal APP-splicing in the presence of elevated IOP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697739 | PMC |
| http://dx.doi.org/10.3109/02713683.2010.494240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unilateral vitritis in an immunocompetent individual - A rare presentation of ocular toxoplasmosis.
Med J Malaysia
January 2025
Department of Ophthalmology, Saveetha Institute of Medical and Technical Sciences (Deemed to be University): SIMATS Deemed University, Chennai, Tamilnadu, India.
Ocular toxoplasmosis is the leading cause of infectious retinochoroiditis in both adults and children. It is caused by the obligate intracellular parasite, Toxoplasma gondii. It is a common cause of posterior uveitis and focal retinitis, typically seen in immunocompetent individuals as a primary infection or in immunocompromised individuals as reactivation of latent infection.
View Article and Find Full Text PDFAssociation of Matrix Metalloproteinases Polymorphisms with Glaucoma Risk, Glaucoma Phenotype, and Response to Treatment with Selective Laser Trabeculoplasty or Latanoprost.
Int J Mol Sci
December 2024
Department of Ophthalmology, University Medical Centre Ljubljana, Grablovičeva 46, 1000 Ljubljana, Slovenia.
In open-angle glaucoma, the increase in intraocular pressure (IOP) is caused by an increased resistance to aqueous humour outflow in the trabecular meshwork. Since genetic variability of matrix metalloproteinase (MMP) genes may influence extracellular matrix remodelling, we investigated their association with glaucoma risk and/or response to treatment. The retrospective part of the study included patients with primary open-angle glaucoma and ocular hypertension (OHT); in the prospective part of the study, newly diagnosed patients with POAG or OHT were randomised to receive either latanoprost or selective laser trabeculoplasty (SLT) as the initial treatment.
View Article and Find Full Text PDFTherapeutic Keratoplasty for Keratitis.
J Clin Med
December 2024
Ophthalmology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
: This study evaluates the effectiveness of therapeutic keratoplasty for fungal keratitis and explores the diagnosis and management challenges of this infectious corneal disease. We retrospectively analyzed therapeutic keratoplasty cases at a tertiary hospital for keratitis when standard treatments failed. : Five cases of keratitis, unresponsive to typical antifungal treatments, required keratoplasty due to fast progression and diagnostic difficulties.
View Article and Find Full Text PDFDiabetes Mellitus: A Risk Factor in Schlemm's Canal-Based Minimally Invasive Glaucoma Surgery.
J Clin Med
December 2024
Sensho-kai Eye Institute, Minamiyama 50-1, Iseda, Kyoto 611-0043, Japan.
The objective of this study was to evaluate the impact of diabetes mellitus (DM) on the outcome of Schlemm's canal-based minimally invasive glaucoma surgery (MIGS). : In a retrospective interventional cohort study, postoperative intraocular pressure (IOP) and intracameral bleeding were analyzed in 25 diabetic patients and 84 non-diabetic patients, with primary open-angle glaucoma (POAG) or ocular hypertension (OH). : The mean follow-up period for all 109 eyes was 35.
View Article and Find Full Text PDFAdvancing Glaucoma Treatment During Pregnancy and Breastfeeding: Contemporary Management Strategies and Prospective Therapeutic Developments.
Biomedicines
November 2024
Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.
The management of glaucoma in pregnancy and breastfeeding requires a careful evaluation of treatment choices to guarantee the well-being of both the mother and the developing fetus. This review explores the intricacies of controlling glaucoma in pregnant and breastfeeding women, including a comprehensive overview of existing glaucoma treatment methods, clinical guidelines, and future therapeutic approaches. The efficacy and safety profiles of traditional treatment approaches, such as topical and systemic medicines and surgical treatments, are evaluated specifically about their use during pregnancy and breastfeeding.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!